Vertex Pharmaceuticals Contingent consideration fair value adjustment increased by 147.4% to $900.00K in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 175.0%, from -$1.20M to $900.00K. Over 4 years (FY 2021 to FY 2025), Contingent consideration fair value adjustment shows an upward trend with a -9.3% CAGR.
A gain (reduction in liability) often suggests that milestones are less likely to be met, while a loss (increase in liability) suggests higher confidence in achieving those milestones.
This metric reflects the periodic revaluation of liabilities related to contingent consideration, such as milestone paym...
Specific to companies that utilize earn-out structures in their M&A activity.
is_nee_contingent_consideration_fair_value_adjustment| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.60M | $1.20M | -$2.00M | -$7.50M | -$49.20M | -$2.60M | $0.00 | -$1.90M | -$600.00K | $1.20M | -$50.30M | -$100.00K | $500.00K | $300.00K | -$1.20M | $2.20M | $900.00K | -$1.90M | $900.00K |
| QoQ Change | — | -25.0% | -266.7% | -275.0% | -556.0% | +94.7% | +100.0% | — | +68.4% | +300.0% | <-999% | +99.8% | +600.0% | -40.0% | -500.0% | +283.3% | -59.1% | -311.1% | +147.4% |
| YoY Change | — | — | — | — | <-999% | -316.7% | +100.0% | +74.7% | +98.8% | +146.2% | — | +94.7% | +183.3% | -75.0% | +97.6% | >999% | +80.0% | -733.3% | +175.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.